O. O. Buriakovska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
O. O. Buriakovska has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Galyna Fadieienko
L. T. Mala National Institute of Therapy of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine
5 shared publications - Oleksiy Gridnyev
Departments the Division for the Study of the Digestive Diseases and Its Comorbidity With Noncommunicable Diseases Government Institution L.T. Malaya Therapy National Institute of NAMS of Ukraine Kharkiv Ukraine
5 shared publications - I. P. Romanova
SI «V. Danilevsky Institute for Endocrine Pathology Problems of the National Academy of Medical Sciences of Ukraine», Department of Clinical Endocrinology, Alchevskykh str., 10, Kharkiv, 61002, Ukraine
3 shared publications - Anna Shalimova
Kharkiv National Medical University, Kharkiv, Ukraine
2 shared publications - Ganna Isayeva
Cardiovascular Research Institute Basel (CRIB), University Heart Center, University Hospital Basel, University of Basel, Switzerland
2 shared publications - Maryna M. Vovchenko
L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine
2 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 2,p. 70-77
Problems of preserving muscle mass during weight loss, particularly in the treatment of obesity and overweight. Review
The article provides data on the main characteristics and functions of muscle tissue in the human body, with special attention paid to the age aspect. The mechanisms of mitochondrial metabolism and β-oxidation of fatty acids during physical activity are described. The definition, prevalence and diagnostic criteria of sarcopenia are given. The existing modern methods of diagnosing sarcopenia are described. The effects of myostatin and adipokines in the development and progression of sarcopenia are described. The pathogenetic mechanisms of the relationship between insulin resistance and the quantity and quality of muscle tissue are carefully described. Special attention is paid to such a phenomenon as myosteatosis. Data from studies in various populations that studied the ratio of adipose and muscle tissue, namely muscle quality and the risk of developing metabolic syndrome, are presented. Data are presented on the possibilities of non-drug effects on the quantity and quality of muscle tissue. The risks of muscle loss during various types of weight loss (both calorie deficit and glucagon-like peptide-1 agonists) are also described. Various treatment options (both pharmacological and non-pharmacological) for sarcopenia are presented. The role of trace elements such as selenium, magnesium, vitamin D, and some amino acids in the formation of muscle mass and improvement of metabolic parameters is also described. The results of studies on the effects and mechanisms of action of landogrosumab, bimagrumab, and semaglutide on overall weight and the quantity and quality of adipose and muscle tissue are presented. The effects of apelin on body composition, optimization of muscle mass and quality are detailed. The data from a recently published phase 1b study of a novel peripherally acting cannabinoid receptor type 1 inverse agonist INV-202 and its effects on metabolism and body composition are described.
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 2,p. 70-77
Open AccessProblems of preserving muscle mass during weight loss, particularly in the treatment of obesity and overweight. Review
The article provides data on the main characteristics and functions of muscle tissue in the human body, with special attention paid to the age aspect. The mechanisms of mitochondrial metabolism and β-oxidation of fatty acids during physical activity are described. The definition, prevalence and diagnostic criteria of sarcopenia are given. The existing modern methods of diagnosing sarcopenia are described. The effects of myostatin and adipokines in the development and progression of sarcopenia are described. The pathogenetic mechanisms of the relationship between insulin resistance and the quantity and quality of muscle tissue are carefully described. Special attention is paid to such a phenomenon as myosteatosis. Data from studies in various populations that studied the ratio of adipose and muscle tissue, namely muscle quality and the risk of developing metabolic syndrome, are presented. Data are presented on the possibilities of non-drug effects on the quantity and quality of muscle tissue. The risks of muscle loss during various types of weight loss (both calorie deficit and glucagon-like peptide-1 agonists) are also described. Various treatment options (both pharmacological and non-pharmacological) for sarcopenia are presented. The role of trace elements such as selenium, magnesium, vitamin D, and some amino acids in the formation of muscle mass and improvement of metabolic parameters is also described. The results of studies on the effects and mechanisms of action of landogrosumab, bimagrumab, and semaglutide on overall weight and the quantity and quality of adipose and muscle tissue are presented. The effects of apelin on body composition, optimization of muscle mass and quality are detailed. The data from a recently published phase 1b study of a novel peripherally acting cannabinoid receptor type 1 inverse agonist INV-202 and its effects on metabolism and body composition are described.
- Open Access
- 31 March 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 16-20
Deintensification of insulin therapy in type 2 diabetes mellitus. Clinical case
Using a clinical example of insulindependent type 2 diabetes mellitus in a young woman, the features of clinical symptoms, the course of the disease, and the difficulties of achieving glycemic targets and weight control in a fairly large cohort of patients are examined. Diabetes mellitus is a very common disease that leads to both serious complications and worsens the course of concomitant diseases. According to the World Health Organization, the rate of development and spread of diabetes mellitus is rapidly increasing every year and is gaining momentum as a pandemic. The most common and most disabling type of diabetes mellitus is type 2. Despite a fairly wide range of oral hypoglycemic drugs, a large number of patients are prescribed insulin therapy due to the progressive nature of diabetes and the inability to achieve glycemic targets. This article emphasizes the importance of a personalized and patientcentered approach to patients with type 2 diabetes mellitus. It details the priorities, risks, and potential adverse effects of adding basalbolus insulin therapy to oral agents in patients with type 2 diabetes mellitus. The complaints, medical history, objective status, laboratory and instrumental data of the patient, who had been obese since childhood, had type 2 diabetes mellitus from the age of 31, and was transferred to insulin therapy from the age of 36, are presented in detail. Possible treatment methods are discussed, combinations of various oral hypoglycemic drugs with insulin therapy in different regimens. A scheme for deintensification of insulin therapy and the dynamics of glycemia indicators according to laboratory data, as well as continuous glycemia monitoring, are presented. The analysis of the literature data on the disease was conducted. It is emphasized that it is necessary to regularly observe such patients for timely correction and selection of therapy and reduce the risk of developing both early and delayed complications.
- 31 March 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 16-20
Open AccessDeintensification of insulin therapy in type 2 diabetes mellitus. Clinical case
Using a clinical example of insulindependent type 2 diabetes mellitus in a young woman, the features of clinical symptoms, the course of the disease, and the difficulties of achieving glycemic targets and weight control in a fairly large cohort of patients are examined. Diabetes mellitus is a very common disease that leads to both serious complications and worsens the course of concomitant diseases. According to the World Health Organization, the rate of development and spread of diabetes mellitus is rapidly increasing every year and is gaining momentum as a pandemic. The most common and most disabling type of diabetes mellitus is type 2. Despite a fairly wide range of oral hypoglycemic drugs, a large number of patients are prescribed insulin therapy due to the progressive nature of diabetes and the inability to achieve glycemic targets. This article emphasizes the importance of a personalized and patientcentered approach to patients with type 2 diabetes mellitus. It details the priorities, risks, and potential adverse effects of adding basalbolus insulin therapy to oral agents in patients with type 2 diabetes mellitus. The complaints, medical history, objective status, laboratory and instrumental data of the patient, who had been obese since childhood, had type 2 diabetes mellitus from the age of 31, and was transferred to insulin therapy from the age of 36, are presented in detail. Possible treatment methods are discussed, combinations of various oral hypoglycemic drugs with insulin therapy in different regimens. A scheme for deintensification of insulin therapy and the dynamics of glycemia indicators according to laboratory data, as well as continuous glycemia monitoring, are presented. The analysis of the literature data on the disease was conducted. It is emphasized that it is necessary to regularly observe such patients for timely correction and selection of therapy and reduce the risk of developing both early and delayed complications.
- Open Access
- 30 December 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 4,p. 33-37
A rare form of type 3c diabetes mellitus. Clinical case
On a clinical example of type 3c diabetes mellitus in a young man of 40 years, the peculiarities of clinical symptoms and the difficulties of diagnosing this disease are considered. Diabetes mellitus is a fairly common disease that leads to severe disabling complications and worsens the course of concomitant diseases. According to the World Health Organization, the rate of development and spread of diabetes is rapidly increasing every year and is gaining momentum as a pandemic. The most common type of diabetes mellitus is type 2. Type 3c diabetes mellitus is a rare form that was first announced in 2011 by the American Diabetes Association together with the World Health Organization. This type of diabetes is secondary diabetes that develops due to the destruction or loss of pancreatic tissue and accounts for up to 8% of all diabetes mellitus cases. In this article, special attention is paid to the importance of thorough examination and follow-up of patients who have undergone acute or chronic inflammatory processes of the pancreas or surgical interventions on the pancreas. The data of a patient who suffered acute pancreatitis in 2014, had regular exacerbations of chronic pancreatitis for 10 years, and had a diabetes mellitus manifest in 2023 are presented in detail. Diagnostic criteria of diabetes mellitus type 3c according to modern recommendations are described. Criteria for differential diagnosis of types of diabetes mellitus are provided. Possible methods of treatment of this disease are discussed. The features of the course of diabetes mellitus type 3c, the risk of developing hypoglycemic states in such patients, and the target glycemic goals, as well as the possibilities of their achievement, are discussed. An analysis of data from the literature of the disease was carried out. It is emphasized that it is necessary to regularly observe such patients for timely diagnosis, selection of correct therapy and reduction of the risk of developing both early and delayed complications.
- 30 December 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 4,p. 33-37
Open AccessA rare form of type 3c diabetes mellitus. Clinical case
On a clinical example of type 3c diabetes mellitus in a young man of 40 years, the peculiarities of clinical symptoms and the difficulties of diagnosing this disease are considered. Diabetes mellitus is a fairly common disease that leads to severe disabling complications and worsens the course of concomitant diseases. According to the World Health Organization, the rate of development and spread of diabetes is rapidly increasing every year and is gaining momentum as a pandemic. The most common type of diabetes mellitus is type 2. Type 3c diabetes mellitus is a rare form that was first announced in 2011 by the American Diabetes Association together with the World Health Organization. This type of diabetes is secondary diabetes that develops due to the destruction or loss of pancreatic tissue and accounts for up to 8% of all diabetes mellitus cases. In this article, special attention is paid to the importance of thorough examination and follow-up of patients who have undergone acute or chronic inflammatory processes of the pancreas or surgical interventions on the pancreas. The data of a patient who suffered acute pancreatitis in 2014, had regular exacerbations of chronic pancreatitis for 10 years, and had a diabetes mellitus manifest in 2023 are presented in detail. Diagnostic criteria of diabetes mellitus type 3c according to modern recommendations are described. Criteria for differential diagnosis of types of diabetes mellitus are provided. Possible methods of treatment of this disease are discussed. The features of the course of diabetes mellitus type 3c, the risk of developing hypoglycemic states in such patients, and the target glycemic goals, as well as the possibilities of their achievement, are discussed. An analysis of data from the literature of the disease was carried out. It is emphasized that it is necessary to regularly observe such patients for timely diagnosis, selection of correct therapy and reduction of the risk of developing both early and delayed complications.
- Open Access
- 26 March 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 1,p. 50-58
New perspectives on treatment of overweight and obesity. Review
Low physical activity, high‑calorie diet due to the formation of a positive energy balance contribute to the development of overweight and obesity and, according to forecasts, their prevalence will increase rapidly worldwide. Excess adipose tissue has negative health consequences (the greatest risks relate to visceral adipose tissue) — the development of type 2 diabetes, cardiovascular diseases, chronic kidney disease, oncology, diseases of the musculoskeletal system and negatively affects psycho‑emotional and social health. Therefore, the problem of weight loss with the subsequent normalization of metabolic processes and risk reduction is extremely relevant in such patients. But unfortunately, not all patients are able to achieve results through lifestyle changes, and this has made pharmacological and surgical methods of treating overweight and obesity more relevant. Over the past two decades, glucagon‑like peptide receptor‑1 agonists have become an important class of drugs for the treatment of obesity. They have proven a high profile of effectiveness in weight loss, but there are a number of limiting factors: achieving the so‑called «plateau effect», as well as the inconvenience of injection. Currently, the development of new glucagon‑like peptide receptor‑1 agonists and its receptors is not stopped in order to increase their effectiveness and ease of use. The first results of their clinical trials are encouraging and promising. Other pharmacological agents (affecting bitter taste receptors, blocking CB1R or restoring endogenous signaling pathways) are also being actively developed and bariatric techniques for the treatment of overweight and obesity are being improved. Special attention is being paid to new effective and safe techniques — intragastric expandable capsules and intestinal barrier implantation.
- 26 March 2025
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 1,p. 50-58
Open AccessNew perspectives on treatment of overweight and obesity. Review
Low physical activity, high‑calorie diet due to the formation of a positive energy balance contribute to the development of overweight and obesity and, according to forecasts, their prevalence will increase rapidly worldwide. Excess adipose tissue has negative health consequences (the greatest risks relate to visceral adipose tissue) — the development of type 2 diabetes, cardiovascular diseases, chronic kidney disease, oncology, diseases of the musculoskeletal system and negatively affects psycho‑emotional and social health. Therefore, the problem of weight loss with the subsequent normalization of metabolic processes and risk reduction is extremely relevant in such patients. But unfortunately, not all patients are able to achieve results through lifestyle changes, and this has made pharmacological and surgical methods of treating overweight and obesity more relevant. Over the past two decades, glucagon‑like peptide receptor‑1 agonists have become an important class of drugs for the treatment of obesity. They have proven a high profile of effectiveness in weight loss, but there are a number of limiting factors: achieving the so‑called «plateau effect», as well as the inconvenience of injection. Currently, the development of new glucagon‑like peptide receptor‑1 agonists and its receptors is not stopped in order to increase their effectiveness and ease of use. The first results of their clinical trials are encouraging and promising. Other pharmacological agents (affecting bitter taste receptors, blocking CB1R or restoring endogenous signaling pathways) are also being actively developed and bariatric techniques for the treatment of overweight and obesity are being improved. Special attention is being paid to new effective and safe techniques — intragastric expandable capsules and intestinal barrier implantation.
- Open Access
- 7 October 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 3,p. 66-71
Type 3c diabetes mellitus: what are we dealing with? Review
The authors presented updated data on the term «type 3 diabetes mellitus», its modern classification, pathophysiological mechanisms of development and features of treatment, its definitions, epidemiology and modern classification based on the recommendations of the American Diabetes Association. Definitions and epidemiological features of acute pancreatitis and its most frequent complications, including 3c type diabetes have been described. Statistical data were presented on the risk of developing complications of acute pancreatitis in the form of carbohydrate metabolism disorders. Historical prerequisites of fatal complications of acute pancreatitis in the form of hyperglycemic states were also described. The pathophysiological mechanisms of the development of type 3c diabetes, namely local and systemic inflammation, loss of islet tissue of the pancreas, dysregulation of the insulinincretin axis, autoimmune destruction of βcells of the pancreas, etc. were highlighted in detail. The role of genetic factors in the development of diabetes against the background of acute pancreatitis is described. Currently there are no standardized unified criteria of type 3c diabetes, thus the main and additional diagnostic criteria according to the different authors have been analyzed in detail. The differential characteristics and features of the diagnosis of diabetes mellitus by type and peculiarities of the diagnosis of type 1, 2 and 3c diabetes mellitus have been presented. The discussion on the glycemic target goals for patients with type 3c diabetes and the need for screening and prevention of carbohydrate metabolism disorders in patients with acute pancreatitis has been outlined. The authors provided current recommendations for the treatment of type 3c diabetes and discussed the possibilities of the use of insulin in the basis/bolus mode to achieve compensation of carbohydrate metabolism. The necessity to compensate pancreas exocrine insufficiency to improve the assimilation of fats and fat‑soluble vitamins has been emphasized.
- 7 October 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 3,p. 66-71
Open AccessType 3c diabetes mellitus: what are we dealing with? Review
The authors presented updated data on the term «type 3 diabetes mellitus», its modern classification, pathophysiological mechanisms of development and features of treatment, its definitions, epidemiology and modern classification based on the recommendations of the American Diabetes Association. Definitions and epidemiological features of acute pancreatitis and its most frequent complications, including 3c type diabetes have been described. Statistical data were presented on the risk of developing complications of acute pancreatitis in the form of carbohydrate metabolism disorders. Historical prerequisites of fatal complications of acute pancreatitis in the form of hyperglycemic states were also described. The pathophysiological mechanisms of the development of type 3c diabetes, namely local and systemic inflammation, loss of islet tissue of the pancreas, dysregulation of the insulinincretin axis, autoimmune destruction of βcells of the pancreas, etc. were highlighted in detail. The role of genetic factors in the development of diabetes against the background of acute pancreatitis is described. Currently there are no standardized unified criteria of type 3c diabetes, thus the main and additional diagnostic criteria according to the different authors have been analyzed in detail. The differential characteristics and features of the diagnosis of diabetes mellitus by type and peculiarities of the diagnosis of type 1, 2 and 3c diabetes mellitus have been presented. The discussion on the glycemic target goals for patients with type 3c diabetes and the need for screening and prevention of carbohydrate metabolism disorders in patients with acute pancreatitis has been outlined. The authors provided current recommendations for the treatment of type 3c diabetes and discussed the possibilities of the use of insulin in the basis/bolus mode to achieve compensation of carbohydrate metabolism. The necessity to compensate pancreas exocrine insufficiency to improve the assimilation of fats and fat‑soluble vitamins has been emphasized.
- Open Access
- 15 June 2024
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 81 (2) , 84-88
РІДКІСНИЙ КЛІНІЧНИЙ ВИПАДОК ВРОДЖЕНОЇ ГІПЕРПЛАЗІЇ КОРИ НАДНИРКОВИХ ЗАЛОЗ
Представлений рідкісний випадок вродженої гіперплазії кори надниркових залоз у пацієнта з класичним варіантом недостатності 21-гідроксилази. Внаслідок антенатальної гіперандрогенії розвинувся хибний жіночий гермафродитизм. Таким чином, при народженні, було помилково зареєстровано чоловічу стать. Діагноз встановлено у тримісячному віці, але, через відмову батьків, патогенетичне лікування не проводилось впродовж багатьох років. Пацієнт виховувався, як хлопчик, гендерної дисфорії не мав. Систематична замісна гормонотерапія преднізолоном розпочата тільки з 31 року після проведеного оперативного втручання – видалення матки з придатками. Додавання до терапії тестостерону та симптоматичних препаратів забезпечило задовільний стан пацієнта, збереження працездатності і чоловічої потенції. Однак вимушена відміна тестостерону та зміна дозування преднізолону привела до декомпенсації та погіршення загального і психо-емоційного стану. Це обумовлено симптомами гіпокортизолемії, зниженням потенції та, як наслідок, напруженими стосунками зі статевим партнером. Корекція замісної терапії забезпечила повернення пацієнта до відносно нормального життя. Звертає на себе увагу той факт, що після видалення матки з придатками та відновлення гормональної терапії у хворого зникли епілептичні скарги. Крім того, на момент теперішнього обстеження виявлено утворення лівого наднирника, що потребує верифікації та спостереження.
- 15 June 2024
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 81 (2) , 84-88
Open AccessРІДКІСНИЙ КЛІНІЧНИЙ ВИПАДОК ВРОДЖЕНОЇ ГІПЕРПЛАЗІЇ КОРИ НАДНИРКОВИХ ЗАЛОЗ
Представлений рідкісний випадок вродженої гіперплазії кори надниркових залоз у пацієнта з класичним варіантом недостатності 21-гідроксилази. Внаслідок антенатальної гіперандрогенії розвинувся хибний жіночий гермафродитизм. Таким чином, при народженні, було помилково зареєстровано чоловічу стать. Діагноз встановлено у тримісячному віці, але, через відмову батьків, патогенетичне лікування не проводилось впродовж багатьох років. Пацієнт виховувався, як хлопчик, гендерної дисфорії не мав. Систематична замісна гормонотерапія преднізолоном розпочата тільки з 31 року після проведеного оперативного втручання – видалення матки з придатками. Додавання до терапії тестостерону та симптоматичних препаратів забезпечило задовільний стан пацієнта, збереження працездатності і чоловічої потенції. Однак вимушена відміна тестостерону та зміна дозування преднізолону привела до декомпенсації та погіршення загального і психо-емоційного стану. Це обумовлено симптомами гіпокортизолемії, зниженням потенції та, як наслідок, напруженими стосунками зі статевим партнером. Корекція замісної терапії забезпечила повернення пацієнта до відносно нормального життя. Звертає на себе увагу той факт, що після видалення матки з придатками та відновлення гормональної терапії у хворого зникли епілептичні скарги. Крім того, на момент теперішнього обстеження виявлено утворення лівого наднирника, що потребує верифікації та спостереження.
- Open Access
- 15 June 2024
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 2,p. 26-37
The contribution of hormonal disorders in the pathogenesis of metabolic-associated steatotic liver disease
The analysis has been performed for the contribution of hormones to the pathogenetic mechanisms of metabolic‑associated steatotic liver disease (MASLD). The role of adipose tissue hormones in the development of metabolic disorders and systemic inflammatory reactions is well investigated and proved. With progression of metabolic‑associated steatohepatitis (MASH), the leptin levels increase, and adiponectin and omentin levels decrease, associating with the proinflammatory and profibrotic state of the liver and impaired glucose metabolism. The liver also produces hormone‑like proteins, hepatokines, which actively affect the extrahepatic regulation of metabolism, namely, contribute to the development of insulin resistance and dyslipidemia. Medications, affecting the endocrinological component of MASLD/MASH pathogenesis, are considered one the of the most promising approaches for the treatment of these diseases. It should be noted that only pioglitazone and glucagon‑like peptide (GLP)‑1 receptor agonists are the two antihyperglycemic drugs with proven efficacy and safety at MASH. Thus, the use of GLP‑1 agonists results in the reduction of food intake, body weight, improvement of glucose control in patients with MASH, they reduce steatosis and insulin resistance, and the level of inflammation in the liver. The data are available indicating the prospect of using dual agonists of GLP‑1/glucagon and GLP‑1 and glucose‑dependent insulinotropic peptide for the treatment of MASLD/MASH. According to preliminary data, such combinations resulted in the decrease in steatosis and improvement in liver fibrosis indicators, though additional proof is required to confirm changes in the histological liver characteristics. Another group of hormones with significant importance in MASLD pathogenesis, are hormones of the adrenal glands (aldosterone, cortisol and androgens), as they take an active part in the regulation of the response to stress and lipolysis. In this aspect, androgens attract special attention, because firstly, both their deficiency and excess will contribute to the development of hepatic steatosis, obesity, insulin resistance and other signs of metabolic syndrome, and secondly, their deficiency will contribute to the development of sarcopenia, which is very important in the aspect of MASLD. A lack of estrogen in women will also contribute to liver steatosis, insulin resistance, dyslipidemia, and obesity. One of the factors affecting the development of liver steatosis can be growth hormone, decrease in its level will contribute to the intrahepatic accumulation of fat, which will increase the risk of MASHP. Thyroid hormones can also play a role in the development of MASLD, the severity of hypothyroidism has a direct correlation with the severity of MASLD, and the levels of thyroid‑stimulating hormone and free thyroxine have an association with liver fibrosis. Проаналізовано внесок гормонів у патогенетичні механізми метаболічно‑асоційованої стеатотичної хвороби печінки (МАСХП). Роль гормонів жирової тканини в розвитку метаболічних порушень і системних запальних реакцій доведена та добре вивчена. З прогресуванням метаболічно‑асоційованого стеатогепатиту (МАСГ) рівень лептину підвищується, а адипонектину та оментину знижується, що асоціюється з прозапальним і профібротичним станом печінки та порушенням обміну глюкози. Печінка також виробляє гормоноподібні протеїни — гепатокіни, які активно впливають на позапечінкову регуляцію метаболізму, а саме сприяють розвитку інсулінорезистентності та дисліпідемії. Одними з найперспективніших для лікування МАСХП/МАСГ вважають препарати, які діють на ендокринологічну складову патогенезу цих захворювань. Лише піоглітазон і агоністи рецепторів глюкагоноподібного пептиду (ГПП)‑1 є антигіперглікемічними препаратами, що мають докази ефективності та безпечності щодо їхнього застосування при МАСГ. Використання агоністів ГПП‑1 знижує споживання їжі, масу тіла, поліпшує контроль рівня глюкози в пацієнтів із MAСГ, зменшує стеатоз, резистентність до інсуліну і ступінь запалення в печінці. Є дані, що свідчать про перспективність застосування подвійних агоністів ГПП‑1/глюкагону та ГПП‑1 і глюкозозалежного інсулінотропного пептиду для лікування МАСХП/МАСГ. За попередніми даними, такі комбінації сприяли зниженню стеатозу та поліпшенню показників фіброзу печінки, але необхідні додаткові докази зміни гістологічних характеристик печінки. Ще однією групою гормонів, яка має важливе значення в патогенезі МАСХП, є гормони надниркових залоз (альдостерон, кортизол,...
- 15 June 2024
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 2,p. 26-37
Open AccessThe contribution of hormonal disorders in the pathogenesis of metabolic-associated steatotic liver disease
The analysis has been performed for the contribution of hormones to the pathogenetic mechanisms of metabolic‑associated steatotic liver disease (MASLD). The role of adipose tissue hormones in the development of metabolic disorders and systemic inflammatory reactions is well investigated and proved. With progression of metabolic‑associated steatohepatitis (MASH), the leptin levels increase, and adiponectin and omentin levels decrease, associating with the proinflammatory and profibrotic state of the liver and impaired glucose metabolism. The liver also produces hormone‑like proteins, hepatokines, which actively affect the extrahepatic regulation of metabolism, namely, contribute to the development of insulin resistance and dyslipidemia. Medications, affecting the endocrinological component of MASLD/MASH pathogenesis, are considered one the of the most promising approaches for the treatment of these diseases. It should be noted that only pioglitazone and glucagon‑like peptide (GLP)‑1 receptor agonists are the two antihyperglycemic drugs with proven efficacy and safety at MASH. Thus, the use of GLP‑1 agonists results in the reduction of food intake, body weight, improvement of glucose control in patients with MASH, they reduce steatosis and insulin resistance, and the level of inflammation in the liver. The data are available indicating the prospect of using dual agonists of GLP‑1/glucagon and GLP‑1 and glucose‑dependent insulinotropic peptide for the treatment of MASLD/MASH. According to preliminary data, such combinations resulted in the decrease in steatosis and improvement in liver fibrosis indicators, though additional proof is required to confirm changes in the histological liver characteristics. Another group of hormones with significant importance in MASLD pathogenesis, are hormones of the adrenal glands (aldosterone, cortisol and androgens), as they take an active part in the regulation of the response to stress and lipolysis. In this aspect, androgens attract special attention, because firstly, both their deficiency and excess will contribute to the development of hepatic steatosis, obesity, insulin resistance and other signs of metabolic syndrome, and secondly, their deficiency will contribute to the development of sarcopenia, which is very important in the aspect of MASLD. A lack of estrogen in women will also contribute to liver steatosis, insulin resistance, dyslipidemia, and obesity. One of the factors affecting the development of liver steatosis can be growth hormone, decrease in its level will contribute to the intrahepatic accumulation of fat, which will increase the risk of MASHP. Thyroid hormones can also play a role in the development of MASLD, the severity of hypothyroidism has a direct correlation with the severity of MASLD, and the levels of thyroid‑stimulating hormone and free thyroxine have an association with liver fibrosis. Проаналізовано внесок гормонів у патогенетичні механізми метаболічно‑асоційованої стеатотичної хвороби печінки (МАСХП). Роль гормонів жирової тканини в розвитку метаболічних порушень і системних запальних реакцій доведена та добре вивчена. З прогресуванням метаболічно‑асоційованого стеатогепатиту (МАСГ) рівень лептину підвищується, а адипонектину та оментину знижується, що асоціюється з прозапальним і профібротичним станом печінки та порушенням обміну глюкози. Печінка також виробляє гормоноподібні протеїни — гепатокіни, які активно впливають на позапечінкову регуляцію метаболізму, а саме сприяють розвитку інсулінорезистентності та дисліпідемії. Одними з найперспективніших для лікування МАСХП/МАСГ вважають препарати, які діють на ендокринологічну складову патогенезу цих захворювань. Лише піоглітазон і агоністи рецепторів глюкагоноподібного пептиду (ГПП)‑1 є антигіперглікемічними препаратами, що мають докази ефективності та безпечності щодо їхнього застосування при МАСГ. Використання агоністів ГПП‑1 знижує споживання їжі, масу тіла, поліпшує контроль рівня глюкози в пацієнтів із MAСГ, зменшує стеатоз, резистентність до інсуліну і ступінь запалення в печінці. Є дані, що свідчать про перспективність застосування подвійних агоністів ГПП‑1/глюкагону та ГПП‑1 і глюкозозалежного інсулінотропного пептиду для лікування МАСХП/МАСГ. За попередніми даними, такі комбінації сприяли зниженню стеатозу та поліпшенню показників фіброзу печінки, але необхідні додаткові докази зміни гістологічних характеристик печінки. Ще однією групою гормонів, яка має важливе значення в патогенезі МАСХП, є гормони надниркових залоз (альдостерон, кортизол,...
- Open Access
- 31 March 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 49-52
Clinical case of autoimmune polyglandular syndrome type II
The peculiarities of clinical symptoms and the difficulties of diagnosing have been considered on the clinical example of manifestations of autoimmune polyglandular syndrome type II in a young woman. Autoimmune polyglandular syndrome type II is a rather rare pathology, its prevalence is 1 : 20.000 cases of the population. The diagnosis of this disease is determined by the presence of insufficiency of at least two endocrine glands with mandatory adrenal insufficiency. The second component of the disease can be any autoimmune thyroid disease or type 1 diabetes mellitus, which is also autoimmune in nature, or both conditions. Adrenal insufficiency is the initial manifestation of this syndrome in approximately 50% of patients, occurs simultaneously with autoimmune thyroiditis or type 1 diabetes in 20% of patients, the remaining 30% of patients may have a different sequence of manifest components of autoimmune polyglandular syndrome type II. In this article, special attention is paid to the importance of careful monitoring of patients with at least one autoimmune disorder of endocrine organ. The data presents in detail a history of patient who had only type 1 diabetes and autoimmune thyroiditis for 7 years, and the manifestation of adrenal insufficiency was registered 7 years after the manifestation of the primary components of autoimmune polyglandular syndrome type II. The authors highlighted diagnostically significant changes in laboratory methods. The analysis has been performed for the literature data, related to the disease. The necessary to observe patients regularly for quick diagnosis and to reduce the risk of developing both immediate and delayed complications has been emphasized. Special attention should be paid to the examination of relatives of the first line of kinship among patients with the established diagnosis of autoimmune polyglandular syndrome type II for the presence of possible heredity.
- 31 March 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 49-52
Open AccessClinical case of autoimmune polyglandular syndrome type II
The peculiarities of clinical symptoms and the difficulties of diagnosing have been considered on the clinical example of manifestations of autoimmune polyglandular syndrome type II in a young woman. Autoimmune polyglandular syndrome type II is a rather rare pathology, its prevalence is 1 : 20.000 cases of the population. The diagnosis of this disease is determined by the presence of insufficiency of at least two endocrine glands with mandatory adrenal insufficiency. The second component of the disease can be any autoimmune thyroid disease or type 1 diabetes mellitus, which is also autoimmune in nature, or both conditions. Adrenal insufficiency is the initial manifestation of this syndrome in approximately 50% of patients, occurs simultaneously with autoimmune thyroiditis or type 1 diabetes in 20% of patients, the remaining 30% of patients may have a different sequence of manifest components of autoimmune polyglandular syndrome type II. In this article, special attention is paid to the importance of careful monitoring of patients with at least one autoimmune disorder of endocrine organ. The data presents in detail a history of patient who had only type 1 diabetes and autoimmune thyroiditis for 7 years, and the manifestation of adrenal insufficiency was registered 7 years after the manifestation of the primary components of autoimmune polyglandular syndrome type II. The authors highlighted diagnostically significant changes in laboratory methods. The analysis has been performed for the literature data, related to the disease. The necessary to observe patients regularly for quick diagnosis and to reduce the risk of developing both immediate and delayed complications has been emphasized. Special attention should be paid to the examination of relatives of the first line of kinship among patients with the established diagnosis of autoimmune polyglandular syndrome type II for the presence of possible heredity.
- Open Access
- 31 October 2023
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 5,p. 70-77
The impact of saccharolytic and proteolytic fermentation products in the pathogenesis of metabolic associated diseases. Review
Висвітлено дані досліджень про роль цукролітичних та протеолітичних продуктів ферментації у патогенетичних механізмах розвитку метаболічно‑асоційованих захворювань. Наведено коротку характеристику складу, чисельності та функції нармального мікробіому кишечника. Представлено дані щодо особливостей цукролітичного та протеолітичного бродіння в кишечнику. Описано роль кишкової мікробіти у формуванні таких метаболічно‑асоційованих захворювань, як ожиріння, цукровий діабет 2 типу та неалкогольна жирова хвороба печінки. Наведено дані щодо впливу коротколанцюгових жирних кислот, а саме: пропіонату, сукцинату й бутирату, у регулюванні обміну та секреції інсуліну, лептипу, а також гормонів насичення — глюкагоноподібного пептиду‑1 і пептиду YY. Висвітлено роль протеолітичних продуктів ферментації в метаболізмі та функціонуванні осі кишечник — печінка, а також їхній вплив на процеси вуглеводного обміну. Описано вплив білково‑ферментаційних продуктів мікробіоти кишечника на прозапальні реакції кишечника та прогресування неалкогольної жирової хвороби печінки. Наведено комбіновані дані (отримані на гризунах та людях) щодо впливу коротколанцюгових жирних кислот на метаболізм жирової тканини. Доведено здатність ацетату інгібувати внутрішньоклітинний ліполіз в адипоцитах. Описано вплив основних коротколанцюгових жирних кислот на кишкову проникність. Зазначено найважливішу роль коротколанцюгових жирних кислот у розвитку запальних процесів, зокрема запалення низької градації, характерного для метаболічно‑асоційованих захворювань. Наведено дані досліджень ролі ацетату, бутирату та пропіонату при неалкогольній жировій хворобі печінки й цукровому діабеті 2 типу.
- 31 October 2023
- Published by Publishing Company VIT-A-POL in Modern Gastroenterology
- No. 5,p. 70-77
Open AccessThe impact of saccharolytic and proteolytic fermentation products in the pathogenesis of metabolic associated diseases. Review
Висвітлено дані досліджень про роль цукролітичних та протеолітичних продуктів ферментації у патогенетичних механізмах розвитку метаболічно‑асоційованих захворювань. Наведено коротку характеристику складу, чисельності та функції нармального мікробіому кишечника. Представлено дані щодо особливостей цукролітичного та протеолітичного бродіння в кишечнику. Описано роль кишкової мікробіти у формуванні таких метаболічно‑асоційованих захворювань, як ожиріння, цукровий діабет 2 типу та неалкогольна жирова хвороба печінки. Наведено дані щодо впливу коротколанцюгових жирних кислот, а саме: пропіонату, сукцинату й бутирату, у регулюванні обміну та секреції інсуліну, лептипу, а також гормонів насичення — глюкагоноподібного пептиду‑1 і пептиду YY. Висвітлено роль протеолітичних продуктів ферментації в метаболізмі та функціонуванні осі кишечник — печінка, а також їхній вплив на процеси вуглеводного обміну. Описано вплив білково‑ферментаційних продуктів мікробіоти кишечника на прозапальні реакції кишечника та прогресування неалкогольної жирової хвороби печінки. Наведено комбіновані дані (отримані на гризунах та людях) щодо впливу коротколанцюгових жирних кислот на метаболізм жирової тканини. Доведено здатність ацетату інгібувати внутрішньоклітинний ліполіз в адипоцитах. Описано вплив основних коротколанцюгових жирних кислот на кишкову проникність. Зазначено найважливішу роль коротколанцюгових жирних кислот у розвитку запальних процесів, зокрема запалення низької градації, характерного для метаболічно‑асоційованих захворювань. Наведено дані досліджень ролі ацетату, бутирату та пропіонату при неалкогольній жировій хворобі печінки й цукровому діабеті 2 типу.
- Open Access
- 27 June 2023
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 2,p. 19-24
The nature of sleep disorders and quality of life against the background of stress in patients with moderate to high cardiovascular risk
Objective — to evaluate the dynamics of sleep quality and duration, as well as quality of life after 12 months of follow‑up in patients with moderate to high cardiovascular risk against the background of stress caused by military actions. Materials and methods. The prospective, open, non‑placebo controlled investigation has been conducted over 12 months with participation of 87 patients with moderate to high cardiovascular risk. Women prevailed among patients (50 (57.5%)), the mean age was (59.39±12.09) years. Obesity of I degree was established in 47.1%, II degree obesity in 32.3%, III degree obesity in 11.8% of patients, and excessive body mass was registered in 8.8% of the examined subjects. There were no subjects with normal body mass. At baseline, essential hypertension of various stages was established in 58.9% of patients. All patients underwent assessment of cardiovascular risk based on Framingham scale, index of quality of life with SF‑36 «Health Status Survey» questionnaire, stress level with Perceived Stress Scale, presence of sleep disorders with the use of criteria of the International Classification of Sleep Disorders (2014), as well as measurement of anthropometric parameters. Results. The prevalence of stress was 100.0% with no significant difference between women (99.8%) and men (100.0%), (OR=0.96 with 95% CI 0.72—1.28). At baseline, circadian disturbances of sleep and alertness prevailed in patients (41%), while after 12 months of observation, insomnia was more common in the entire observation group (55.8%). At the end of the study, the number of patients who had difficulty falling asleep increased (from 35.3% to 81.2%, р <0.05), who had difficulty maintaining uninterrupted sleep (from 38.2% to 66.6%, р <0.05), who had awakening before the planned time (from 58.8% to 75.0%, р <0.05), who had nausea/vomiting as a manifestation of sleep disturbance (from 17.6% to 37.5%, р <0.05), who had deterioration of attention/concentration/memory (from 58.8% to 77.1%, р <0.05). Conclusions. Against the background of chronic stress, insomnia prevailed among all sleep disorders in patients with moderate to high cardiovascular risk. As a result of the study, the significant decrease in the quality of life index from 69.7% to 43.2% has been established in this category of patients against the background of chronic stress.
- 27 June 2023
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 2,p. 19-24
Open AccessThe nature of sleep disorders and quality of life against the background of stress in patients with moderate to high cardiovascular risk
Objective — to evaluate the dynamics of sleep quality and duration, as well as quality of life after 12 months of follow‑up in patients with moderate to high cardiovascular risk against the background of stress caused by military actions. Materials and methods. The prospective, open, non‑placebo controlled investigation has been conducted over 12 months with participation of 87 patients with moderate to high cardiovascular risk. Women prevailed among patients (50 (57.5%)), the mean age was (59.39±12.09) years. Obesity of I degree was established in 47.1%, II degree obesity in 32.3%, III degree obesity in 11.8% of patients, and excessive body mass was registered in 8.8% of the examined subjects. There were no subjects with normal body mass. At baseline, essential hypertension of various stages was established in 58.9% of patients. All patients underwent assessment of cardiovascular risk based on Framingham scale, index of quality of life with SF‑36 «Health Status Survey» questionnaire, stress level with Perceived Stress Scale, presence of sleep disorders with the use of criteria of the International Classification of Sleep Disorders (2014), as well as measurement of anthropometric parameters. Results. The prevalence of stress was 100.0% with no significant difference between women (99.8%) and men (100.0%), (OR=0.96 with 95% CI 0.72—1.28). At baseline, circadian disturbances of sleep and alertness prevailed in patients (41%), while after 12 months of observation, insomnia was more common in the entire observation group (55.8%). At the end of the study, the number of patients who had difficulty falling asleep increased (from 35.3% to 81.2%, р <0.05), who had difficulty maintaining uninterrupted sleep (from 38.2% to 66.6%, р <0.05), who had awakening before the planned time (from 58.8% to 75.0%, р <0.05), who had nausea/vomiting as a manifestation of sleep disturbance (from 17.6% to 37.5%, р <0.05), who had deterioration of attention/concentration/memory (from 58.8% to 77.1%, р <0.05). Conclusions. Against the background of chronic stress, insomnia prevailed among all sleep disorders in patients with moderate to high cardiovascular risk. As a result of the study, the significant decrease in the quality of life index from 69.7% to 43.2% has been established in this category of patients against the background of chronic stress.